Inhibition of TSH/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of Thyroid Eye Disease. Krieger CC, Sui X, Kahaly GJ, Neumann S, et al. J Clin Endocrinol Metab 2021 Nov 12. pii: 6426158. doi: 10.1210.

Read + Share

Amedeo Smart

Independent Medical Education

Krieger CC, Sui X, Kahaly GJ, Neumann S, et al. Inhibition of TSH/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of Thyroid Eye Disease. J Clin Endocrinol Metab 2021 Nov 12. pii: 6426158. doi: 10.1210.
PMID: 34788857